Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress

Free Radical Biology and Medicine

Volumn 49, Issue 5, 2010, Pages 857-864

  Ferrante, Elisabetta ^a   Vazzana, Natale ^a   Santilli, Francesca ^a   Di Cicco, Maria ^b   Lauriti, Ciro ^b   Di Battista, Luciano ^b   Ciabattoni, Giovanni ^c   Di Matteo, Luigi ^b   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ospedale Civile di Pescara   (Italy)

^c Department of Drug Sciences   (Italy)

Author keywords

Free radicals; Oxidative stress; Platelet activation; RAGE; Rheumatoid arthritis; Thromboxane

Indexed keywords

11 DEHYDRO THROMBOXANE B2; 8 ISO PROSTAGLANDIN F2 ALPHA; ADALIMUMAB; ADVANCED GLYCATION END PRODUCT RECEPTOR; CORTICOSTEROID; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROSTAGLANDIN F2 ALPHA; THROMBOXANE; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; URINE LEVEL;

EID: 77955095336     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.06.009     Document Type: Article

References (44)

1. Kremers H.M., Crowson C.S., Therneau T.M., Roger V.L., Gabriel S.E. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study. Arthritis Rheum. 2008, 58:2268-2274.
2. Tyrrell P.N., Beyene J., Feldman B.M., McCrindle B.W., Silverman E.D., Bradley T.J. Rheumatic disease and carotid intima-media thickness: A systematic review and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1014-1026.
3. Stamatelopoulos K.S., Kitas G.D., Papamichael C.M., Chryssohoou E., Kyrkou K., Georgiopoulos G., Protogerou A., Panoulas V.F., Sandoo A., Tentolouris N., Mavrikakis M., Sfikakis P.P. Atherosclerosis in rheumatoid arthritis versus diabetes: A comparative study. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1702-1708.
4. Peters M.J., van Halm V.P., Voskuyl A.E., Smulders Y.M., Boers M., Lems W.F., Visser M., Stehouwer C.D., Dekker J.M., Nijpels G., Heine R., Dijkmans B.A., Nurmohamed M.T. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 2009, 61:1571-1579.
5. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001, 44:2737-2745.
6. Gonzalez A., Maradit Kremers H., Crowson C.S., Ballman K.V., Roger V.L., Jacobsen S.J., O'Fallon W.M., Gabriel S.E. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann. Rheum. Dis. 2008, 67:64-69.
7. Frostegård J. Rheumatic diseases: Insights into inflammation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:892-893.
8. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
9. Quyyumi A.A. Inflamed joints and stiff arteries: Is rheumatoid arthritis a cardiovascular risk factor?. Circulation 2006, 114:1137-1139.
10. Davì G., Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357:2482-2494.
11. Davì G., Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 2005, 14:760-764.
12. Ferroni P., Santilli F., Guadagni F., Basili S., Davì G. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr. Med. Chem. 2007, 14:2170-2180.
13. Limb G.A., Webster L., Soomro H., Janikoun S., Shilling J. Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin. Exp. Immunol. 1999, 118:213-218.
14. Pignatelli P., De Biase L., Lenti L., Tocci G., Brunelli A., Cangemi R., Riondino S., Grego S., Volpe M., Violi F. Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood 2005, 106:1992-1994.
15. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108:949-955.
16. Verweij C.L. How RAGE turns in rage. Genes Immun. 2002, 3:117-118.
17. Santilli F., Vazzana N., Bucciarelli L.G., Davì G. Soluble forms of RAGE in human diseases: Clinical and therapeutical implications. Curr. Med. Chem. 2009, 16:940-952.
18. Vazzana N., Santilli F., Cuccurullo C., Davì G. Soluble forms of RAGE in internal medicine. Intern. Emerg. Med. 2009, 4:389-401.
19. Pullerits R., Bokarewa M., Dahlberg L., Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther. 2005, 7:R817-R824.
20. Koyama H., Shoji T., Fukumoto S., Shinohara K., Emoto M., Mori K., Tahara H., Ishimura E., Kakiya R., Tabata T., Yamamoto H., Nishizawa Y. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:147-153.
21. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., Emoto M., Shoji T., Tamei H., Matsuki H., Sakurai S., Yamamoto Y., Yonekura H., Watanabe T., Yamamoto H., Nishizawa Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2587-2593.
22. Taniguchi N., Kawahara K., Yone K., Hashiguchi T., Yamakuchi M., Goto M., Inoue K., Yamada S., Ijiri K., Matsunaga S., Nakajima T., Komiya S., Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48:971-981.
23. Patrono C., Falco A., Davì G. Isoprostane formation and inhibition in atherothrombosis. Curr. Opin. Pharmacol. 2005, 5:198-203.
24. Kageyama Y., Takahashi M., Ichikawa T., Torikai E., Nagano A. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2008, 26:73-80.
25. Kageyama Y., Takahashi M., Nagafusa T., Torikai E., Nagano A. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol. Int. 2008, 28:245-251.
26. Ferro D., Basili S., Roccaforte S., Di Franco M., Cipollone F., Ciabattoni G., Davì G. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Arthritis Rheum. 1999, 42:2689-2697.
27. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315-324.
28. Wang Z., Ciabattoni G., Créminon C., Lawson J., Fitzgerald G.A., Patrono C., Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J. Pharmacol. Exp. Ther. 1995, 275:94-100.
29. 2 in human plasma and urine. Biochim. Biophys. Acta 1987, 918:293-297.
30. Avalos I., Chung C.P., Oeser A., Milne G.L., Borntrager H., Morrow J.D., Raggi P., Solus J., Stein C.M. Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus 2007, 16:981-986.
31. Sakon S., Xue X., Takekawa M., Sasazuki T., Okazaki T., Kojima Y., Piao J.H., Yagita H., Okumura K., Doi T., Nakano H. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 2003, 22:3898-3909.
32. Hitchon C.A., El-Gabalawy H.S. Oxidation in rheumatoid arthritis. Arthritis Res. Ther. 2004, 6:265-278.
33. Basu S., Whiteman M., Mattey D.L., Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann. Rheum. Dis. 2001, 60:627-631.
34. 4 excretion in patients with rheumatoid arthritis. Prostaglandins Leukotrienes. Essent. Fatty Acids 2001, 65:301-306.
35. Zhang H., Park Y., Wu J., Chen X., Lee S., Yang J., Dellsperger K.C., Zhang C. Role of TNF-alpha in vascular dysfunction. Clin. Sci. (London) 2009, 116:219-230.
36. Taniguchi N., Kawahara K., Yone K., Hashiguchi T., Yamakuchi M., Goto M., Inoue K., Yamada S., Ijiri K., Matsunaga S., Nakajima T., Komiya S., Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48:971-981.
37. Hofmann M.A., Drury S., Hudson B.I., Gleason M.R., Qu W., Lu Y., Lalla E., Chitnis S., Monteiro J., Stickland M.H., Bucciarelli L.G., Moser B., Moxley G., Itescu S., Grant P.J., Gregersen P.K., Stern D.M., Schmidt A.M. RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002, 3:123-135.
38. Williams R.O., Feldmann M., Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 1992, 89:9784-9788.
39. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 2006, 355:704-701.
40. Cuchacovich R., Espinoza L.R. Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?. Clin. Rheumatol. 2009, 28:1217-1220.
41. Popa C., van den Hoogen F.H., Radstake T.R., Netea M.G., Eijsbouts A.E., den Heijer M., van der Meer J.W., van Riel P.L., Stalenhoef A.F., Barrera P. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:1503-1507.
42. Gao X., Zhang H., Schmidt A.M., Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H491-H498.
43. Sundberg E., Grundtman C., Af Klint E., Lindberg J., Ernestam S., Ulfgren A.K., Harris H.E., Andersson U. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients-a prospective clinical study. Arthritis Res. Ther. 2008, 10:R33.
44. Gabriel S.E. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am. J. Med. 2008, 121:S9-S14.